PRECIGEN, INC. Operating Lease Cost
PRECIGEN, INC. (PGEN) reported Operating Lease Cost of $412.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-04
- PRECIGEN, INC. operating lease, cost for the quarter ending 2026-06-30 was $412.00K, a 0.72% decline year-over-year.
- PRECIGEN, INC. operating lease, cost for the quarter ending 2026-03-31 was $407.00K, a 2.16% decline year-over-year.
- PRECIGEN, INC. operating lease, cost for the quarter ending 2025-12-31 was $339.00K, a 58.86% decline year-over-year.
- PRECIGEN, INC. operating lease, cost for the quarter ending 2025-09-30 was $423.00K, a 25.52% increase year-over-year.
- PRECIGEN, INC. operating lease, cost for fiscal 2025 was $1.59M, a 33.04% decline from fiscal 2024.
- PRECIGEN, INC. operating lease, cost for fiscal 2024 was $2.38M, a 6.49% increase from fiscal 2023.
- PRECIGEN, INC. operating lease, cost for fiscal 2023 was $2.23M, a 8.59% decline from fiscal 2022.
- PRECIGEN, INC. operating lease, cost for fiscal 2022 was $2.44M, a 14.90% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 9 month as first filed | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $412.00K 10-Q · filed 2026-08-04 | $819.00K 10-Q · filed 2026-08-04 | $1.16M derived: sum of 3 quarters · filed 2026-08-04 | $1.58M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $407.00K 10-Q · filed 2026-05-13 | $746.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.17M derived: sum of 3 quarters · filed 2026-05-13 | $1.58M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $339.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $762.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.18M derived: sum of 3 quarters · filed 2026-08-04 | $1.59M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $423.00K 10-Q · filed 2025-11-13 | $838.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.25M 10-Q · filed 2025-11-13 | $2.08M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $415.00K 10-Q · filed 2026-08-04 | $831.00K 10-Q · filed 2026-08-04 | $1.66M derived: sum of 3 quarters · filed 2026-08-04 | $1.99M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $416.00K 10-Q · filed 2026-05-13 | $1.24M derived: sum of 2 quarters · filed 2026-05-13 | $1.58M derived: sum of 3 quarters · filed 2026-05-13 | $2.19M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $824.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.16M derived: sum of 2 quarters · filed 2026-03-25 | $1.77M derived: sum of 3 quarters · filed 2026-03-25 | $2.38M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $337.00K 10-Q · filed 2025-11-13 | $946.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.55M 10-Q · filed 2025-11-13 | $1.94M derived: sum of 4 quarters · filed 2026-03-25 | ||||
| 2024-06-30 | $609.00K 10-Q · filed 2025-08-12 | $1.22M 10-Q · filed 2025-08-12 | $1.60M derived: sum of 3 quarters · filed 2026-03-25 | $2.22M derived: sum of 4 quarters · filed 2026-03-25 | ||||
| 2024-03-31 | $609.00K 10-Q · filed 2025-05-14 | $990.00K derived: sum of 2 quarters · filed 2026-03-25 | $1.61M derived: sum of 3 quarters · filed 2026-03-25 | $2.23M derived: sum of 4 quarters · filed 2026-03-25 | ||||
| 2023-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.00M derived: sum of 2 quarters · filed 2026-03-25 | $1.62M derived: sum of 3 quarters · filed 2026-03-25 | $2.23M 10-K · filed 2026-03-25 | ||||
| 2023-09-30 | $621.00K 10-Q · filed 2024-11-14 | $1.24M derived: sum of 2 quarters · filed 2024-11-14 | $1.85M 10-Q · filed 2024-11-14 | $2.46M derived: sum of 4 quarters · filed 2025-03-19 | ||||
| 2023-06-30 | $617.00K 10-Q · filed 2024-08-14 | $1.23M 10-Q · filed 2024-08-14 | $1.84M derived: sum of 3 quarters · filed 2025-03-19 | $2.44M derived: sum of 4 quarters · filed 2025-03-19 | ||||
| 2023-03-31 | $615.00K 10-Q · filed 2024-05-14 | $1.22M derived: sum of 2 quarters · filed 2025-03-19 | $1.82M derived: sum of 3 quarters · filed 2025-03-19 | $2.43M derived: sum of 4 quarters · filed 2025-03-19 | ||||
| 2022-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $1.20M derived: sum of 2 quarters · filed 2025-03-19 | $1.82M derived: sum of 3 quarters · filed 2025-03-19 | $2.44M 10-K · filed 2025-03-19 | ||||
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-09 | $1.21M derived: sum of 2 quarters · filed 2023-11-09 | $1.84M 10-Q · filed 2023-11-09 | $2.42M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $613.00K 10-Q · filed 2023-08-09 | $1.24M 10-Q · filed 2023-08-09 | $1.82M derived: sum of 3 quarters · filed 2024-03-19 | $2.59M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $627.00K 10-Q · filed 2023-05-10 | $729.00K 10-Q · filed 2022-05-09 | $1.21M derived: sum of 2 quarters · filed 2024-03-19 | $1.98M derived: sum of 3 quarters · filed 2024-03-19 | $2.73M derived: sum of 4 quarters · filed 2024-03-19 | |||
| 2021-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.35M derived: sum of 2 quarters · filed 2024-03-19 | $2.11M derived: sum of 3 quarters · filed 2024-03-19 | $2.87M 10-K · filed 2024-03-19 | $3.26M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $770.00K 10-Q · filed 2022-11-09 | $843.00K 10-Q · filed 2021-11-08 | $1.52M derived: sum of 2 quarters · filed 2022-11-09 | $2.29M 10-Q · filed 2022-11-09 | $2.51M 10-Q · filed 2021-11-08 | $2.91M derived: sum of 4 quarters · filed 2023-03-06 | ||
| 2021-06-30 | $755.00K 10-Q · filed 2022-08-08 | $829.00K 10-Q · filed 2021-08-09 | $1.52M 10-Q · filed 2022-08-08 | $1.67M 10-Q · filed 2021-08-09 | $2.14M derived: sum of 3 quarters · filed 2023-03-06 | $3.04M derived: sum of 4 quarters · filed 2023-03-06 | ||
| 2021-03-31 | $839.00K 10-Q · filed 2022-05-09 | $1.39M derived: sum of 2 quarters · filed 2023-03-06 | $2.28M derived: sum of 3 quarters · filed 2023-03-06 | $3.18M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2020-12-31 | $549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $1.44M derived: sum of 2 quarters · filed 2023-03-06 | $2.34M derived: sum of 3 quarters · filed 2023-03-06 | $3.24M 10-K · filed 2023-03-06 | $3.58M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $892.00K 10-Q · filed 2021-11-08 | $1.80M 10-Q · filed 2020-11-09 | $1.79M derived: sum of 2 quarters · filed 2021-11-08 | $2.69M 10-Q · filed 2021-11-08 | $5.32M 10-Q · filed 2020-11-09 | $1.07M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $897.00K 10-Q · filed 2021-08-09 | $1.76M 10-Q · filed 2020-08-10 | $1.80M 10-Q · filed 2021-08-09 | $3.52M 10-Q · filed 2020-08-10 | $180.00K derived: sum of 3 quarters · filed 2022-03-01 | $2.00M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $901.00K 10-Q · filed 2021-05-10 | $1.76M 10-Q · filed 2020-05-11 | -$717.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.10M derived: sum of 3 quarters · filed 2022-03-01 | $2.88M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $203.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.98M derived: sum of 3 quarters · filed 2022-03-01 | $3.82M 10-K · filed 2022-03-01 | $7.26M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | $1.82M 10-Q · filed 2020-11-09 | $2.67M 10-Q · filed 2019-11-12 | $3.60M derived: sum of 2 quarters · filed 2020-11-09 | $5.44M 10-Q · filed 2020-11-09 | $7.71M 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $1.78M 10-Q · filed 2020-08-10 | $2.52M 10-Q · filed 2019-08-09 | $3.62M 10-Q · filed 2020-08-10 | $5.05M 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $1.84M 10-Q · filed 2020-05-11 | $2.53M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |